Welcome, Guest. Please login or register.
November 24, 2024, 03:07:28 pm

Login with username, password and session length


Members
Stats
  • Total Posts: 55133
  • Total Topics: 4851
  • Online Today: 238
  • Online Ever: 3061
  • (September 25, 2024, 11:40:40 pm)
Users Online
Users: 0
Guests: 218
Total: 218

Welcome

Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Hep C Drugs Are Highly Effective, but There’s Still Room for Improvement  (Read 5891 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 784
    • Hep Mag
A meta-analysis of major clinical trials of hepatitis C virus (HCV) treatments has concluded what is increasingly apparent in the era of direct-acting antiviral therapy: The drugs are highly effective. There is room for improvement, however, as subgroups of the hep C population still have unaddressed needs.

Publishing their findings in the Annals of Internal Medicine, researchers reviewed data from 42 published clinical trials of eight-week—or longer—courses of the following direct-acting antiviral (DAA) regimens: Harvoni (ledipasvir/sofosbuvir); Olysio (simeprevir) and Sovaldi (sofosbuvir); Daklinza (daclatasvir) and Sovaldi; Viekira Pak (ombitasvir/paritaprevir/ritonavir; dasabuvir); Zepatier (grazoprevir/elbasvir); Technivie (ombitasvir/paritaprevir/ritonavir); and Epclusa (sofosbuvir/velpatasvir). Ribavirin was sometimes given as an adjunct to DAA therapy.

For more...
https://www.hepmag.com/article/hep-c-drugs-highly-effective-still-room-improvement

 


© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.